Ability Pharmaceuticals, SA

Spain · 18 Employees
Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. AbilityPharma's is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel. ABTL0812 has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d'Hebron Institut d'Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard). ABTL0812 is the first cancer drug killing tumor cells through potent cytotoxic autophagy via inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress). Its unique mechanism of action was partially published at Clinical Cancer Research in December 2015 and fully characterized at Autophagy journal in May 2020. The compound has also immunomodulatory effects, turning "cold" immunogenic tumors into "hot" immunogenic. The compound is active as standalone treatment, it has synergy with chemotherapy, and it has synergy with anti PD1 therapies. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma. ABTL0812 has been granted Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, by the US FDA and the European EMA. Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc.

概述

国家 Spain
成立时间 2009
总部 edifici eureka, campus de la uab, bellaterra, cerdanyola del vallès, catalunya, spain
电话号码 +34 935 86 89 77
网站 http://www.abilitypharma.com
LinkedIn http://www.linkedin.com/company/abilitypharma
Twitter http://twitter.com/abilitypharma
Facebook http://www.facebook.com/AbilityPharma
员工数 18
行业 biotechnology,
简介 Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. AbilityPharma's is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel. ABTL0812 has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d'Hebron Institut d'Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard). ABTL0812 is the first cancer drug killing tumor cells through potent cytotoxic autophagy via inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress). Its unique mechanism of action was partially published at Clinical Cancer Research in December 2015 and fully characterized at Autophagy journal in May 2020. The compound has also immunomodulatory effects, turning "cold" immunogenic tumors into "hot" immunogenic. The compound is active as standalone treatment, it has synergy with chemotherapy, and it has synergy with anti PD1 therapies. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma. ABTL0812 has been granted Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, by the US FDA and the European EMA. Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc.

技术

Apache

Load Balancers

Gmail

Email Providers

Google Analytics

Analytics and Tracking

Google Apps

Other

Google Maps

Other

Microsoft Office 365

Other

Mobile Friendly

Other

常见问题

Ability Pharmaceuticals, SA 在哪里?

Ability Pharmaceuticals, SA 的总部位于 edifici eureka, campus de la uab, bellaterra, cerdanyola del vallès, catalunya, spain

Ability Pharmaceuticals, SA 的电话号码是多少?

Ability Pharmaceuticals, SA 的电话号码是 +34 935 86 89 77

Ability Pharmaceuticals, SA 的官方网站是什么?

Ability Pharmaceuticals, SA 的公司官方网站是 http://www.abilitypharma.com

Ability Pharmaceuticals, SA 是做什么的?

Ability Pharmaceuticals, SA 的业务有哪些?

Ability Pharmaceuticals, SA 的年收入是多少?

Ability Pharmaceuticals, SA 的收入是 5424000美元

Ability Pharmaceuticals, SA 有多少员工?

Ability Pharmaceuticals, SA 有 18 名员工

Ability Pharmaceuticals, SA 属于哪个行业?

Ability Pharmaceuticals, SA 从事以下行业: biotechnology

Ability Pharmaceuticals, SA 使用什么技术?

Ability Pharmaceuticals, SA 使用的一些流行技术包括: Apache,Gmail,Google Analytics,Google Apps,Google Maps,Microsoft Office 365,Mobile Friendly

如何联系 Ability Pharmaceuticals, SA?

Ability Pharmaceuticals, SA 联系信息: 电话号码:+34 935 86 89 77, 网站:http://www.abilitypharma.com, 邮箱:ema***@***.com

Ability Pharmaceuticals, SA 的社交媒体链接是什么?

Ability Pharmaceuticals, SA 领英:http://www.linkedin.com/company/abilitypharma,fackbook:http://www.facebook.com/AbilityPharma,twitte:http://twitter.com/abilitypharma

Ability Pharmaceuticals, SA 是一家上市公司吗?

不是

Ability Pharmaceuticals, SA 的最后一轮融资是什么时候?

Ability Pharmaceuticals, SA在2020-11-17T00:00:00.000+00:00结束了最后一轮融资,金额达2M€。

谁投资 Ability Pharmaceuticals, SA?

Ability Pharmaceuticals, SA 有 5 家投资者,包括 、U.S. Drug Enforcement Agency、、Inveready、。

管理层

Marc Cortal

Director, Clinical Research

Hector Montoyo

Director of Project Management and Biological Research in Ability Pharmaceuticals

Oriol Gamez

Clinical Science Manager

员工

Elisabet Roda

LabManager & Cancer Research Technician

Carles Domenech

Executive Chairman and Chief Executive Officer

Andrea Segura

Clinical Research Associate

外贸获客 查找关键决策人

10亿+海关交易数据,1.2亿企业数据,2亿+企业联系人数据,1000千万真实采购商。覆盖200+个国家及地区,95%外贸重点拓展市场,可根据行业、经营范围等多方位挖掘目标客户。
免费试用

Top-ranked on G2 Crowd

全球B2B企业库 海关贸易数据 展会采购数据

工作更少,成就更大,销售更聪明

查找更多 B2B 联系人,丰富并验证记录
Email Address

全球B2B企业库

海关贸易数据

展会采购数据

Top-ranked on G2 Crowd

OR
Sign Up with Google